From “Safe Harbor” To Spotlight: Pharmacogenomics Comes Of Age At FDA
This article was originally published in RPM Report
Executive Summary
An FDA/industry workshop on pharmacogenomics and biomarkers highlighted how far the regulatory system for PKG has evolved. Where industry was afraid to share data with FDA, the conversation is now about how to get the agency the resources it needs to review the data effectively.